Summary
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Korro Bio Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 6 | $48 | $78.48 | $30.48 | 63.5% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 22 | $249.04 | $285.78 | $36.74 | 14.75% |
| DP Drew Phillips Fortitude Family Office LLC | 39 | $441 | $491.01 | $50.01 | 11.34% |
 Kevin Kroskey True Wealth Design LLC | 99 | $1,121 | $1,289.97 | $168.97 | 15.07% |
| WPA Wealth Preservation Advisors LLC Wealth Preservation Advisors LLC | 44 | $498 | $551.76 | $53.76 | 10.8% |
Korro Bio Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SS Steven Seedhouse Raymond James | 153.12 | $1,989.09 | $1,893.85 | -$95.24 | -4.79% |
 Yigal Nochomovitz Citigroup | 375.94 | $4,271.06 | $4,616.54 | $345.48 | 8.09% |
Korro Bio Inc. (KRRO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Korro Bio Inc. ever had a stock split?
Korro Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ram Aiyar CEO | NASDAQ (CM) Exchange | 500946108 CUSIP |
| US Country | 49 Employees | - Last Dividend | 6 Nov 2023 Last Split | - IPO Date |
Overview
Korro Bio, Inc. is a pioneering biopharmaceutical company deeply involved in the vibrant field of genetic medicine, with a particular focus on advancing RNA editing technologies. Founded in 2018, the company has established its headquarters in Cambridge, Massachusetts, a notable hub for biotech innovation. With a mission to confront and conquer rare as well as widespread diseases, Korro Bio dedicates itself to the development and commercialization of groundbreaking genetic therapies. Utilizing its proprietary RNA editing platform, OPERA, the company is at the forefront of creating novel RNA editing product candidates designed to modify the course of various diseases by precisely targeting and manipulating genetic information at the RNA level. This innovative approach holds immense potential for providing significant therapeutic benefits across a spectrum of disorders, thereby positioning Korro Bio as a leader in the transformative field of genetic medicine.
Products and Services
- KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD)
As the flagship product candidate of Korro Bio, KRRO-110 is currently in preclinical trials targeting the treatment of Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder that can result in severe lung and liver disease. Through the innovative application of the OPERA RNA editing platform, KRRO-110 aims to correct or mitigate the genetic mutations responsible for AATD, offering new hope for patients with this condition.
- RNA Editing Platform: OPERA
OPERA stands as Korro Bio’s cutting-edge RNA editing platform that underpins all of its product development efforts. This sophisticated technology platform is designed to enable precise and programmable editing of RNA, paving the way for the generation of differentiated RNA editing product candidates. OPERA’s versatility and precision offer considerable advantages in developing therapies for a range of diseases by directly modifying the RNA molecules responsible for disease phenotypes.
- Development Programs for Neurological and Liver Diseases
Expanding its research and development initiatives beyond AATD, Korro Bio is also channeling resources into developing treatments for other significant conditions such as Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS), both of which are debilitating neurological disorders with considerable unmet medical needs. In addition, the company is working on a program aimed at severe alcohol-associated hepatitis, a serious liver condition. These efforts reflect Korro Bio’s commitment to leveraging its RNA editing technology to address a broad spectrum of diseases.
- Pain Management Programs
Understanding the critical challenge of managing severe and chronic pain, Korro Bio is exploring innovative approaches to pain management through its RNA editing platform. By targeting specific subsets of pain with novel genetic therapies, the company aims to develop more effective and safer alternatives to traditional pain management methods, potentially transforming pain management practices.
